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Abstract
Repeat imaging data sets performed on patients with cancer are becoming publicly available. The potential utility
of these data sets for addressing important questions in imaging biomarker development is vast. In particular,
these data sets may be useful to help characterize the variability of quantitative parameters derived from imaging.
This article reviews statistical analysis that may be performed to use results of repeat imaging to 1) calculate the
level of change in parameter value that may be seen in individual patients to confidently characterize that patient as
showing true parameter change, 2) calculate the level of change in parameters value that may be seen in individual
patients to confidently categorize that patient as showing true lack of parameter change, 3) determine if different
imaging devices are interchangeable from the standpoint of repeatability, and 4) estimate the numbers of patients
needed to precisely calculate repeatability. In addition, we recommend a set of statistical parameters that should
be reported when the repeatability of continuous parameters is studied.
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Introduction
Validation of quantitative imaging biomarkers for specific clinical
applications has been a focus of many recent research efforts. The
success of these endeavors may potentially be of significant benefit
to a large group of patients with a variety of diseases [1]. In the field
of oncology, imaging biomarkers may be used to increase our under-
standing of tumor and patient heterogeneity, to document drug de-
livery to target tissues, to elucidate drug mechanisms of actions, to
monitor treatment side effects, and, perhaps most importantly, to
evaluate treatment response [2,3].
The potential utility of an imaging biomarker to measure a biologic
process can be severely hampered by a lack of repeatability or re-
producibility. (For the purpose of this article, we refer to repeatability
as consistency of quantitative results obtained when the same imag-
ing test is performed at short intervals on the same subjects or test
objects using the same equipment in the same center, as distin-
guished from reproducibility, the consistency of results obtained when
the same imaging test is performed at short intervals on the same
subjects or test objects using different equipment in different cen-
ters.) The derivation of reproducible quantitative parameters from
imaging can pose enormous challenges [4–6]. The level of repeat-
ability or reproducibility needed to successfully use a biomarker is
critically dependent on the intended application; for example, the
requirements needed for an imaging test to detect a biologic effect
of a treatment in a large cohort of patients are considerably less strin-
gent than the requirements for the same test to reliably predict a suc-
cessful treatment response in a single patient.
Unfortunately, although an understanding of a technique’s repeat-
ability is necessary to interpret the significance of a test result for in-
dividual patients, repeat image sets to evaluate the repeatability of
quantitative imaging techniques are relatively rarely obtained [7]. Re-
cent efforts to promote the performance of repeat imaging studies
and to make the image data publicly available for use in research
applications, including the Reference Image Database to Evaluate
Response to Therapy (RIDER) project of the National Cancer Insti-
tute’s Cancer Imaging Program [8,9] and related efforts discussed in
this publication, are in the early stages of addressing this need.
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Appropriate Statistical Methods
The increasing availability of public databases of repeat examinations
raises the question of what are appropriate statistical methods for
analyzing quantitative parameters obtained from repeat imaging data
sets. Unfortunately, inappropriate statistical methods, such as the use
of correlation coefficients to measure the agreement between two re-
peated measurements, have been common in the published literature
[10]. Further complicating matters, the types of statistical analyses
that are most appropriate depend to a great extent on the nature
of the research question being addressed.
Bland and Altman [11] provided an intuitive methodology using
the concept of limits of agreement for assessing agreement between
two methods of clinical measurement. Barnhart et al. [12] provided
an overview on the evolution of various statistical methodologies on
assessing agreement over the past several decades. In this article, we
focus on the issue of repeatability only and address appropriate sta-
tistical analysis that can use information from repeat imaging data
sets in four different scenarios. In addition, we will suggest statistical
parameters that should be reported in studies of repeatability and
discuss other potential applications for statistical analysis of repeat
imaging data sets.
For the scenarios described below, we assume that the presence of
change or lack of change in a quantitative imaging biomarker is of in-
terest to the researcher. In this situation, the presence of variability in
the extracted parameter, whether due to patient-related or imaging
system-related factors, can make a measured change in the parameter
difficult to interpret. Statistical tests derived from the analysis of re-
peat data sets can be used, for example, to help determine whether
this variability can account for an observed level of change in param-
eter. In addition, we assume that the parameter extracted from im-
aging is continuous and normally distributed, that the repeatability is
similar across subjects and does not depend on the subject’s true pa-
rameter value or other characteristics of the subject, and that there is
no systematic change in the subject or test object imaged during the
interval between repeated studies.
In the first two scenarios, we try to determine if there is true
change in an individual patient or not. Owing to random error, in-
dividual patients may fall into one of three categories: 1) definite
change is present with 95% confidence, 2) definite no change is pres-
ent with 95% confidence, and 3) unable to determine if there is a
change or not. Scenario 1 deals with the first category and scenario
2 deals with the second. There may be a large group of patients in the
third category; it may be possible to reduce the number of patients in
this category by estimating the repeatability with higher precision. To
accomplish this, we can design a larger study of repeat measurements
with a prespecified level of precision on the estimate of repeatability,
as described in scenario 4. Scenario 3 deals with interchangeability of
devices when we only know the repeatability of particular parameters
in the repeat data sets, where different imaging devices were used in
different sets of patients.
The following notations are used for the repeated data sets. Let Yik
be the observed value for the ith subject at the kth replication, i =
1, …, n; k = 1, … K . The one-way analysis of variance (ANOVA)
model Yik = μi + ɛik can be used to express the observed value as
the true value plus the within-subject error with between-subject
variance σB
2 = Var(μi) and within-subject variance σW
2 = Var(ɛik).
Hence, the total variance is σ T
2 = σ B
2 + σW
2 . Let BMS and WMS be
the between-subject means of squares and within-subject means of
squares obtained from the one-way ANOVA model or calculated by
BMS = K ∑i = 1n (Y¯i − Y¯ )2 / n and WMS = ∑i = 1n ∑k = 1K (Yik − Y¯i)2 /
n(K − 1), where Y¯i is the average over replication for subject i and Y¯
is the grand mean over all observations. We can also calculate tSD =ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðBMS + ðK − 1ÞWMSÞ= Kp , bSD = ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðBMS − WMSÞ = Kp , and
wSD =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
WMS
p
, which are the unbiased estimates of σT, σB, and
σW, respectively. The tSD is useful for the design of future studies if
Y is chosen as the primary outcome because tSD can be used as an
estimate of the standard error of the outcome. The repeatability co-
efficient (RC) is defined as RC = 1:96
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2σ2W
p
=2.77σW and can
be estimated by RĈ = 2.77wSD. Note that the interpretation of RC
is that the difference between any two readings on the same subject is
expected to be from −RC to RC for 95% of subjects. If there are
only two repetitions (K = 2) per subject, wSD is the SD of the differ-
ences divided by
ﬃﬃﬃ
2
p
. Because the WMS is distributed as χn(K − 1)
2 σW
2 /
n(K − 1), the 95% confidence interval (CI) for σW is (σˆL, σˆU) where
σˆL =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
nðK − 1ÞWMS =χ2nðK − 1Þð0:975Þ
q
, σˆU =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
nðK − 1ÞWMSp /ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
χ2nðK − 1Þð0:025Þ
q
, and χn(K − 1)
2 (a) is the ath percentile of the χ 2 dis-
tribution with n(K − 1) degrees of freedom. The corresponding 95%
CI for RC is (RCL, RCU) = (2.77σˆL, 2.77σˆU). A relative measure of
repeatability is the within-subject coefficient of variation (wCV) de-
fined as wCV = σW / μ where μ = E(μi) is the mean of true value. This
measure is sometimes called error rate.
Scenario 1: What Level of Change in Parameter Should Be
Observed to Be Confident That There Has Been a True
Change in the Parameter in an Individual Patient?
The presence of change in a biomarker after therapy may be useful
to identify a group of patients in whom therapy has resulted in a
specific biologic effect. Straightforward examples of this in cancer im-
aging would include studies of change in volume of a lung nodule by
volumetric computed tomography or change in standardized uptake
value in 18F-fluorodeoxyglucose positron emission tomography after
therapy relative to pretreatment baseline values. If such changes can
be validated as surrogate markers of treatment response, the potential
impact on patient care is obvious. Alternatively, association of change
in biomarker with particular patient or disease characteristics can be
helpful to elucidate treatment mechanisms of action; for example, it
may be of interest to identify whether only particular subgroups of
tumors or patients demonstrate a particular biologic response.
To assess whether there is an overall change in the group after treat-
ment, paired analysis (e.g., paired t-test if differences are normally dis-
tributed or nonparametric Wilcoxon test if not) is appropriate. But to
determine whether treatment has resulted in a change in parameter
for an individual patient, use of 95% CI for estimated RC [11] can
provide a reasonable approach for determining whether the observed
change is a true change. Specifically, let Yij = μij + ɛij be the observed
measurements before ( j = pre) and after ( j = post) the therapy for the
ith subject, where μij and ɛij are the true value and measurement error
for subject i at time j, respectively. A true individual change corre-
sponds to μipost − μipre ≠ 0.
Because there may be small levels of change that are considered
inconsequential in the context of an individual trial, it is helpful to
consider a more general situation in which (−δc, δc) is the interval
within which the magnitude of parameter change is considered essen-
tially unchanged; for example, a level of change so small that no ther-
apeutic benefit is expected. In this case, a true individual change
corresponds to |μipost − μipre| ≥ δc. Assume that conditional on subject
i, the measurement errors ɛipre, ɛipost are independent and have the
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same error variance of σW
2 for all subjects. This assumption implies
that the random repetition error does not depend on the subject’s
true parameter value or on subject characteristics. Then Yipost − Yipre
has mean μipost − μipre and variance of 2σW2 . Thus, the 95% CI
for μipost − μipre is

Yipost − Yipre − 1:96 ×
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2σW
p
;Yipost − Yipre +
1:96 ×
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2σW
p 
or (Yipost − Yipre − RC, Yipost − Yipre + RC). If this
CI is outside (−δc, δc), then we are 95% confident that a change has
occurred for this individual, assuming we know the true value of RC.
Thus, the RC provides a reasonable approach for determining whether
the observed change is a true change or not.
One problem in implementing this approach in practice is that the
RC is not known with certainty. Moreover, an RC estimated from a
large number of repeat data sets is generally more reliable than a co-
efficient estimated from a smaller number. By calculating 95% CI for
the RC, (RCL, RCU), we can take into account the effect of the num-
ber of repeat data sets on the degree of uncertainty around the esti-
mate of the RC and generate a conservative estimate of the level of
parameter change that would allow individual patients with true
change to be identified. Using this approach, we can only be 95%
confident that a change has occurred for an individual patient if
the interval (Yipost − Yipre − RCL, Yipost − Yipre + RCU) lies outside
(−δc, δc).
If only a single direction of change is of interest, then a one-sided
confidence limit may be applied. For example, to determine if the
measurement has increased or not, we would like to determine if
μipost − μipre > δc. The lower limit for the one-sided 95% CI is
Yipost − Yipre − 1:645
ﬃﬃﬃﬃﬃ
2σˆ
p
L. If this limit is greater than δc, then we
are 95% confident that a positive change has occurred.
For the specific instance in which we are studying whether a change
of any magnitude occurred in a patient, no matter how small (i.e., when
δc = 0), when both directions of change are of interest, we can only be
95% confident that a change has occurred for an individual patient if
the interval (Yipost − Yipre − RCL, Yipost − Yipre + RCU) does not contain
zero. When only a single direction of change is of interest, a one-sided
CI is used; for example, if only an increase in parameter is of interest,
we can only be 95% confident that a change has occurred when
Yipost − Yipre − 1:645
ﬃﬃﬃﬃﬃ
2σˆ
p
L is greater than zero.
Scenario 2: What Level of Change in Parameter Should Be
Observed to Be Confident There Has Been No Change
in the Parameter in an Individual Patient?
Although the utility of identifying patients who demonstrate an
actual change in a parameter may be obvious, the ability to reliably
identify individual patients who do not exhibit change after treat-
ment may also be of value. Given the expense and side effects of a
particular therapy, one application of quantitative imaging may be to
definitively identify patients who did not experience, for example, a
beneficial pharmacodynamic change from therapy. This result of the
imaging might be used to justify discontinuation of therapy, partic-
ularly if further studies show that lack of pharmacodynamic change
corresponds reliably to poor clinical outcomes.
In considering this scenario, two situations should be considered.
In the first situation, we would like to identify patients who show no
change in a parameter and distinguish this patient group from those
who either had an increase or decrease in the parameter. In this sit-
uation, it is assumed that it remains unclear whether a change in pa-
rameter in either direction may represent a therapeutic effect. In the
second situation, we would like to identify patients who show either
no change in a parameter or change in one direction in the parameter
and distinguish this patient group from those who have the opposite
direction of change. In this situation, a direction of change of param-
eter corresponding to a therapeutic effect is presumed to be known.
Again, consider (−δc, δc) to be the interval within which mag-
nitude of parameter change is so small that no therapeutic benefit
is expected. Then the patient is considered to have no change if
the interval (Yipost − Yipre − RCL, Yipost − Yipre + RCU) is contained
inside of (−δc, δc). However, if the direction of parameter change
corresponding to therapeutic benefit is known and if (for example)
increase in parameter values indicates benefit, we can similarly use
the RC to identify individuals who had either no change or decrease
in parameter value and thus warrant discontinuation of therapy.
In this case, we are 95% confident that subjects with Yipost −
Yipre + 1:645
ﬃﬃﬃﬃﬃ
2σˆ
p
U < δc had either no change or decrease in param-
eter value.
Scenario 3: Assuming Two Imaging Devices Are Measuring the
Same Parameter, Are Two Devices Interchangeable as Far as
Repeatability Is Concerned?
The question of whether different imaging devices are inter-
changeable is of considerable practical importance in cancer imaging,
particularly when devising clinical trials. To reduce variability in clin-
ical trials in which repeated quantitative imaging measurements are
made, imaging studies are often required to be performed on the
same piece of equipment. This requirement may result in difficulty
with patient scheduling; moreover, imaging equipment hardware or
software upgrades occurring while the clinical trial is taking place
may affect the accuracy or reproducibility of the quantitative imaging
parameter extraction.
The question of whether the quantitative results of a specific image
acquisition and analysis protocol are interchangeable with another is
also of interest outside the clinical trials context. The possibility that
these results can be influenced by the characteristics of imaging de-
vices (e.g., field strength of MR magnets used to study proton spec-
troscopy [13]), acquisition protocols (e.g., scan timing and duration
used in oncologic 18F-fluorodeoxyglucose positron emission tomog-
raphy studies [14]), and image analysis software (e.g., software used
for measuring tumor perfusion from multidetector computed tomog-
raphy data [15]) is well known. Different modalities may be used to
extract similar physiological parameters such as tumor blood volume
or flow [16]; if parameter accuracy is validated for a modality that is
not widely available, expensive, or exposes patients to risks, it may be
possible to show that parameters extracted by a more widely available,
inexpensive, and/or safer modality give equivalent clinical information.
To compare the accuracy of two imaging devices, an independent
ground truth is necessary, which repeat imaging sets do not provide.
Repeat image sets do, however, allow the repeatability of two tech-
niques to be compared, assuming that the imaged patient groups are
similar. If the same group of patients were measured by two different
imaging devices in the repeat data sets, both intradevice repeatability
and interdevice agreement (variability) may be assessed. In this case,
we can determine whether the two devices can be used interchange-
ably or not by assessing interdevice agreement with statistical ap-
proaches for assessing agreement [11,12].
Often, however, different image patient groups were used by dif-
ferent devices in the repeated data sets. In this case, if there are no
systematic differences between the quantitative parameters extracted
related to the device used to perform the imaging, the technique with
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smaller repeatability may be preferred or the devices may be used
interchangeably if the repeatability is similar.
Considering this situation, let Yijk = μij + ɛijk, i = 1, …, nj be the
observed measurements for the ith subject by the jth device at the
k th replication, where μij, ɛijk are the “true” value and measurement
errors by device j for subject i. If there is no systematic bias between
the devices, then μij = μi for all j, the “true” parameter value produced
by the devices. Let σWj
2 be the variance of measurement error by
device j. To determine if the repeatability in one device is different
from the repeatability in the other device, one can test hypothesis
H0: σW1
2 = σW2
2 versus H1: σW1
2 ≠ σW22 . If different sets of patients
were used in the measurements by different devices, test of this hy-
pothesis test can be accomplished by an F -test or Levene test for
equality of variance. This can be accomplished by using the option
“HOVTEST” in the mean statement in SAS procedure GLM with
one-way ANOVA model for outcome variable of Zijk = Yijk − Y
-
ij ,
where Y
-
ij is the average reading for the ith subject by the jth device
over the replications. Another simple way to test this hypothesis is to
use the two group t-test for |Zijk| because the mean of this absolute
value is proportional to σWj when the data is normally distributed.
The paired t-test may be used if the same sets of patients were used
for measurements by different devices. A note of caution is that the
test for equality of variance may have low power and the failure to
reject the null hypothesis only means that there is no sufficient evi-
dence to conclude that the repeatability is unequal.
To establish whether the repeatability is equivalent or not, we
would need to carry out an equivalence test. In this case, we need
to choose an equivalence margin δv (>1), which is the acceptable ra-
tio in RCs for the two devices to be considered interchangeable. The
hypothesis we want to test then is in the form of H0: σW1/σW2 ≥ δv
or σW1/σW2 ≤ 1/δv versus H1: 1/δv < σW1/σW2 < δv. This hypothesis
can be decomposed into two one-sided hypotheses that can be tested
by two F -tests [17].
Scenario 4: How Can Analysis of Small Repeat Data Sets Be
Used to Estimate How Many Patients Would Be Needed to
Power a Larger Trial of Repeat Data Sets to Determine the
Repeatability of a Quantitative Image Parameter to a
Particular Degree of Accuracy?
In scenarios 1 and 2, we provided a statistical rationale for classifying
individual patients as “changed” or “unchanged” based on the observed
change in quantitative imaging parameter. Because the RC is never
known with absolute certainty, there is always a range of observed
changes from which the change classification is undetermined. Narrow-
ing the CIs for the RC as well as the magnitude of the RC is needed to
have a smaller group of patients fall into this undetermined range; this
can be partially achieved if the sample size in repeat data sets sufficiently
large that the RC can be estimated precisely. Small repeat data sets can
be used to help design these larger studies to have the desired precision.
Ideally, we would like to have RCU ≤ δc, where δc is the magnitude
of parameter’s positive change that is of interest for measurement in
the trial; for example, δc could be the minimum amount of change in
parameter value considered to indicate a therapeutic benefit to a pa-
tient. When designing a study of repeat data sets to estimate RC, a
sufficient number of subjects and replications should be performed
so that if the study finds that RCU > δc, this result is unlikely to be
due to chance alone. The equation χn(K − 1)
2 (α) / (n(K − 1)) ≥ (RC/δc)2
can be used to determine the number of trial subjects (n) and replica-
tions per subject (K ) required to calculate CIs at the level of 1 − α. For
example, if K = 2 and the RC is 80% of δc, we will need a sample size
of 48 to be 95% confident (α / 2 = 0.025) that RCU ≤ δc. However, if
RC is 90% of δc, we will need a sample size of 192 subjects.
Small repeat data sets can be useful for planning larger trials of repeat
imaging by providing initial estimates of RC for the equation above.
Often, the parameter δc will also not be known with certainty, in which
case an estimate obtained from other studies (e.g., from a prior treatment
imaging trial or by extrapolation from animal studies) may be used.
Discussion
In the early stages of biomarker development, the technical perfor-
mance of an imaging test is often evaluated by measurements of sen-
sitivity and specificity or receiver operating characteristic analysis
[18]. Single-center clinical trials to demonstrate proof of concept
for clinical use often follow. Measurements of imaging biomarker
reproducibility, although often mentioned as an important step in
imaging biomarker development [5], are relatively less commonly ob-
tained [7], perhaps for reasons of expense, patient tolerance, and/or
increased risk to patients. As the analyses above indicate, repeatability
of quantitative image parameter extraction is a major factor in deter-
mining whether a change in parameter value can be detected in a
practical way for individual patients in a clinical care setting.
The analyses above can also be extended to consider the planning of
a multicenter clinical trial, assuming that there are several candidate im-
aging protocol/parameter sets that could be implemented and that the
degree of parameter change corresponding to a positive therapeutic re-
sult is reasonably well understood. If the RC for a particular parameter
is large relative to the size of change (Δ) in parameter believed to cor-
respond with a therapeutic effect, it is unlikely that measurements of
change in this parameter can be measured with sufficient reliability
to be used in clinical decision making; parameters that are highly re-
peatable and that show large changes after successful treatment (i.e.,
RC/Δ < 1) have much more promise in this regard.
Given the high cost of implementation of multicenter imaging
trials, comparison of the size of treatment effect to the RC could
serve as a means to “triage” candidate imaging protocol/parameter
sets; those with high treatment-related parameter change size relative
to RC would be considered promising for inclusion in multicenter
trials, particularly when identification of imaging techniques that
can be translated into standard clinical practice is a study goal. In
contrast, those with high RC relative to treatment effect size would
require more development work aimed at increasing reproducibility
before being considered in a multicenter trial.
Because of the relatively rarity of repeatabilitymeasurements for quan-
titative parameters in the radiology literature and the possible utility of
these measurements for several purposes, we suggest that, at minimum,
studies of repeatability report the following values for each parameter:
 Number of subjects (n) with nonmissing value
 Number of replications (K )
 Mean, total SD tSD =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðBMS + ðK − 1ÞWMSÞ = K Þp , and
range of observed parameter values
 Mean, within-subject SD (wSD, or SD of differences divided
by
ﬃﬃﬃ
2
p
if K = 2), and range of differences in parameter value
 Repeatabi l i ty coeff ic ient est imated by 2.77wSD or
2:77
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
WMS
p
with corresponding 95% CI (RCL, RCU)
One may also report the within-subject coefficient of variation
(wCV), variance ratio (VR = between-subject variance/within-subject
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variance), and the intraclass correlation coefficient (ICC), where the
wCV can be estimated by wCV = wSD/Y¯, VR can be estimated by
VR = (tSD2 − wSD2) / wSD2, and the ICC can be estimated by
ICC = (tSD2 − wSD2) / tSD2 based on the above minimum statistics.
Although we illustrated that RC is useful in determining whether
there is a change for an individual patient, we caution that this ap-
proach depends on a key assumption that RC is the same for all pa-
tients. If the RC depends on the magnitude of the parameter for that
patient or if the RC varies for different subgroups of patients with
particular characteristics, then RC as a function of the parameter
or multiple RCs for different subgroups should be estimated to better
evaluate parameter change for individual patients while taking into
account the patient’s specific characteristics. The dependency of
RC on patient’s characteristics can only be assessed with a large num-
ber of replications (K > 2) and/or sufficient sample sizes within the
subgroups to get precise estimates of multiple RCs.
One limitation of this review is that we considered only a limited
number of scenarios and assumed the quantitative imaging parameter
was a single metric derived from each patient. Because images show
the distribution of parameters in space, they allow hypotheses about
locations and distributions of parameter value distribution to be tested
(e.g., lesional analysis in which patients may have variable numbers of
lesions), which are beyond the scope of this article.
In summary, the public availability of repeat imaging data sets provides
new opportunities for study of variability of quantitative parameters de-
rived from imaging. When use of these parameters in a clinical context is
contemplated, issues of parameter reproducibility and repeatability be-
come particularly important. In this article, we discuss four questions that
can be addressed using data from repeat imaging data sets and appropri-
ate statistical approaches that can be used to help answer these questions.
Because of their value as a test bed for activities such as software devel-
opment and validation, the inclusion of repeat imaging data sets in pub-
licly accessible databases should be encouraged. Recognizing that this is
not always practical, we also recommend a minimal set of statistics that
should be reported when particular results from these data sets are de-
scribed in the literature. Inclusion of a common set of statistics may be
helpful in several instances; for example, when comparing results ob-
tained across several different laboratories; when determining whether
two imaging devices are likely to be interchangeable as far as repeatabil-
ity is concerned; and when planning larger trials of test-retest imaging.
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